Di Vona et al. show that the Down syndrome-associated kinase DYRK1A regulates transcription of a subset of genes by associating to their proximal promoter regions and phosphorylating the CTD of the RNA polymerase II.
INTRODUCTION
The view on how protein kinases might translate cell signaling into the regulation of gene expression programs has been expanded in the possible substrates beyond the paradigmatic transcription factors and co-regulators to encompass histones, chromatin remodelers, or other components of the basal transcription machinery that are directly modified at specific genomic loci (reviewed in Suganuma and Workman, 2013) . In some cases, the recruitment of a kinase to chromatin sites could facilitate the local modification of components of the basal transcription machinery, transcription factors, or regulators (Suganuma and Workman, 2013) . In other cases, chromatin itself is the target for the activity of protein kinases, which, by phosphorylating histones, can epigenetically control target gene expression (reviewed in Baek, 2011) .
DYRK1A (dual-specificity tyrosine-regulated kinase) is a protein kinase that belongs to a highly conserved family of kinases within the CMGC group of the eukaryotic kinome (reviewed in Aranda et al., 2011) . Human DYRK1A maps to chromosome 21, and it is overexpressed in Down syndrome (DS) individuals and DS mouse models. This alteration has been correlated with a wide range of the pathological phenotypes associated to DS, such as motor alterations, retinal abnormalities, osteoporotic bone phenotype, craniofacial dysmorphology, or increased risk of childhood leukemia (Arron et al., 2006; Laguna et al., 2008; Lee et al., 2009; Malinge et al., 2012; Ortiz-Abalia et al., 2008) . In addition, a few cases of truncating mutations in one DYRK1A allele have been described in patients with general growth retardation and severe primary microcephaly (Courcet et al., 2012; Møller et al., 2008; van Bon et al., 2011) , highlighting the extreme dosage sensitivity of this gene. Moreover, and as an indication of the pleiotropic activities of DYRK1A, dysregulation of this kinase has also been linked to tumor growth and pancreatic dysfunction (Pozo et al., 2013; Rachdi et al., 2014) .
DYRK1A substrates are both nuclear and cytosolic proteins reflecting the presence of DYRK1A in these two cellular compartments Kaczmarski et al., 2014) . While cytosolic proteins represent the most abundant DYRK1A targets, there are a few examples of DYRK1A phosphorylation events altering the subcellular localization of transcription factors or splicing factors (Arron et al., 2006; Fernandez-Martinez et al., 2009; Gwack et al., 2006; Qian et al., 2011) . However, most of the nuclear DYRK1A substrates are proteins that shuttle to and from the nucleus, and thus, DYRK1A phosphorylation may well occur in the cytoplasm. Therefore, the role of DYRK1A within the nuclear compartment remains largely unexplored. Hence, we have investigated DYRK1A nuclear activities and found that nuclear DYRK1A interacts with and phosphorylates the RNAPII C-terminal domain (CTD) at Ser2 and Ser5. Furthermore, we show that DYRK1A associates with the promoters of genes actively transcribed by RNAPII, where it regulates transcription by locally phosphorylating CTD residues involved in transcriptional elongation.
RESULTS
Nuclear DYRK1A Is Associated with High Molecular Weight Complexes that Co-Fractionate with RNAPII The DYRK1A protein kinase has been detected in both the nucleus and cytosol of mouse neural cells (Kaczmarski et al., 2014; Martí et al., 2003) . In HeLa cells, although most DYRK1A is found in the cytoplasm, a fraction of the kinase ($10%) could be detected in the nuclear compartment, as assessed by nuclear-cytoplasmic fractionation ( Figure 1A ). The in vitro kinase (IVK) activity of nuclear DYRK1A was comparable to that of the more abundant cytoplasmic protein (Figures 1B and S1A) . Moreover, distinct phosphorylated proteins were evident in the DYRK1A nuclear immunoprecipitates in addition to autophosphorylated DYRK1A ( Figure 1C ). These co-immunoprecipitated proteins were specifically phosphorylated by DYRK1A, as they were not labeled in the presence of the DYRK inhibitor harmine ( Figure 1C ).
The existence of DYRK1A substrates in DYRK1A-specific immunocomplexes led us to hypothesize that DYRK1A might participate in different nuclear complexes. To test this hypothesis, HeLa nuclear extracts were fractionated by ultracentrifugation on a glycerol gradient, and the presence of DYRK1A was assessed in immunoblots. DYRK1A sedimented in distinct regions of the gradient, suggesting its engagement in complexes of different sizes ( Figure 1D ). DYRK1A was present in fractions corresponding to its predicted molecular weight of 86 kDa, an indication of the existence of a soluble monomeric pool of DYRK1A within the nucleus. However, most of the DYRK1A was found in complexes of 150-250 kDa, while an additional pool of DYRK1A was found in fractions 16-22, indicating its incorporation into larger complexes. These high molecular weight fractions were enriched in the RNAPII core enzyme (550 kDa-600 kDa), as detected by immunoblot of its largest subunit, as well as in other proteins of the basal transcriptional machinery, such as the components of the positive transcription elongation factor b (P-TEFb) complex, cyclin T1, and cyclindependent kinase 9 (CDK9). In addition, both the hypo-and hyperphosphorylated forms of the RNAPII large subunit existed in the nuclear DYRK1A immunocomplexes ( Figure 1E ), suggesting that DYRK1A was part of RNAPII-containing complexes in vivo.
DYRK1A Acts as a Transcriptional Activator when Tethered to a Promoter
Given the ability of DYRK1A to interact with RNAPII, we investigated whether DYRK1A could regulate transcription. To this aim, DYRK1A was targeted to a promoter by fusing it to a sequencespecific DNA binding domain (the yeast Gal4 transcription factor: G4DBD), and this fusion protein was assayed for transcriptional activity on reporters containing Gal4-DNA binding sequences in the context of either a minimal promoter (TATA box) or the complex HIV-1 promoter that responds to activation by CDK9 ( Figure S1B ). The G4DBD-DYRK1A fusion protein efficiently activated transcription in a dose-dependent manner . By contrast, activation of these reporters was greatly reduced when G4DBD was fused to a catalytically inactive DYRK1A , confirming that kinase activity is required for DYRK1A transcriptional activity and ruling out that transcriptional activation was due to a cryptic activation domain of DYRK1A tethered through Gal4.
The five human DYRKs are phylogenetically classified as class I or class II ( Figure 1G ) (Aranda et al., 2011) . To assess whether all members of the DYRK family display transcriptional activity, one-hybrid experiments with G4DBD fusion proteins for all DYRKs were performed on the G4E1b-Luc reporter. When expressed at a level similar to that of DYRK1A, only the closest paralog DYRK1B induced transcription ( Figure 1G ). Thus, class I DYRKs act as transcriptional activators when recruited to promoter regulatory regions.
Genome-wide DYRK1A-Chromatin Interactions Identify Proximal Promoter Regions as Targets of DYRK1A The ability of DYRK1A to activate transcription when tethered to a minimal promoter could reflect a role for DYRK1A in transcriptional regulation when recruited to regulatory regions of chromatin. Thus, we sought to map the genome-wide profile of DYRK1A interactions with chromatin by carrying out chromatin immunoprecipitation experiments followed by massive parallel sequencing (ChIP-seq). Around 500 high-confidence peaks were identified in the glioblastoma cell line T98G (Table S1 and Supplemental Experimental Procedures). Notably, location analysis revealed occupancy predominantly within promoter regions (61.7%; Figures 2A and S2A) . Indeed, when the relative position of the DYRK1A-enriched regions was plotted with respect to their closest transcription start site (TSS), the majority of the DYRK1A peaks covered a narrow region upstream of the TSS ( Figure 2B ), indicating that DYRK1A associated with proximal promoter regions. Among the remaining sites, less than 10% corresponded to gene bodies, mostly within introns (7%), and the remaining 29% of the DYRK1A regions were located in regions that did not pertain to any of the genomic regions considered ( Figure 2A ). ChIP-seq experiments were also performed in HeLa cells, and although the number of DYRK1A-associated peaks was smaller (Supplemental Experimental Procedures), all of them fully overlapped with the T98G cell peaks (Figures  S2B and S2C and Table S1 ).
To validate the recruitment of DYRK1A to chromatin, independent ChIP analysis coupled with qPCR (ChIP-qPCR) was performed on selected DYRK1A targets. DYRK1A was found to be markedly enriched at all the genomic regions tested, whereas no enrichment was observed at random genomic regions used as negative controls ( Figures 2C and 2D ). For further validation of the ChIP data, the shape of the predicted peaks was tested by ChIP-qPCR on a randomly selected DYRK1A genomic binding region using primers inside and outside of the predicted binding site. While no enrichment was observed in the external regions, progressive enrichment was observed when approaching the center of the DYRK1A binding region ( Figure 2E ). Finally, the binding of DYRK1A to these genomic loci appeared to be specific, as the ChIP-qPCR values were lower when DYRK1A expression was downregulated by lentiviral delivery of a DYRK1A-specific shRNA ( Figure 2F ).
DYRK1A Regulates the Expression of Its Target Genes
To investigate the relationship between DYRK1A promoter occupancy and the transcriptional activity of its target genes, we (B) DYRK1A kinase activity of DYRK1A immunocomplexes isolated from the cytosolic (C) and nuclear (N) fractions using DYRKtide as a substrate for the times indicated. Immunocomplexes obtained with mouse IgGs were used as controls. The graph shows one representative experiment as the mean ± SD of technical triplicates (see also Figure S1A ). (C) Anti-DYRK1A (IP DYRK1A) and mouse IgG immunoprecipitates (IP Control IgG) from HeLa nuclear extracts (HNE) were subjected to a hot IVK assay in the presence or absence of harmine (10 mM). The proteins labeled were analyzed by autoradiography. The large arrowhead indicates the position of DYRK1A, and the small arrowheads indicate the protein bands phosphorylated in the DYRK1A immunocomplexes.
(D) HNEs were fractionated by sedimentation through a 10%-40% glycerol gradient, and the fractions were analyzed in immunoblots probed with antibodies to the proteins indicated.
(E) DYRK1A immunocomplexes from HNE were analyzed in immunoblots to detect RNAPII (N20 recognizes the hypo-and the hyperphosphorylated IIa and IIo forms).
(F) DYRK1A induces transcription when tethered to a promoter region (see Figure S1B for schematic representation of the effector and reporter plasmids). A chimeric Gal4-DBD fusion of DYRK1A induces luciferase expression from a G4E1b-Luc reporter in a dose-dependent manner, unlike the catalytically inactive mutant (KR) (see also Figures S1E-S1G ).
(G) Transcriptional activity of DYRK family members in one-hybrid reporter assays on the G4E1b-Luc reporter. The upper panel shows a schematic representation of human DYRK proteins and a simplified tree for their phylogenetic relationship. In (F) and (G), the graphs represent transcriptional activity as the fold change compared to the control G4-DBD value (À), established as 1 (mean ± SD), and the data correspond to one representative experiment of three performed. Equivalent expression of the G4-DBD fusions was verified in immunoblots ( Figures S1C  and S1D ).
first analyzed the correlation of DYRK1A peaks with the presence of features that define gene activity (Barski et al., 2007) . DYRK1A peaks overlapped with nucleosome-depleted regions, as seen by the deep cleft in acetylated H3 variants and by the marked depletion of histone marks at the center of the ChIP regions ( Figure 3A) . Moreover, RNAPII occupancy was observed at the DYRK1A peaks ( Figure 3A) . Finally, DYRK1A-bound promoters showed a higher occurrence of activating chromatin modifications when compared with genes that did not associate with DYRK1A, including high levels of H3K4me3 and H3K4me2 surrounding TSSs or elevated H3K36me3 in the gene body ( Figures 3C and S3A) . Hence, the genes that bind DYRK1A appear to maintain an open chromatin state, and they should therefore be actively transcribed in normal growth conditions. Next, we assessed whether DYRK1A depletion altered the expression of downstream target genes. Microarray analysis of T98G cells infected with a lentivirus expressing a shControl or a shRNA specific for DYRK1A showed that the expression of around 30% of the genes that bound DYRK1A at their promoter region was reduced in the kinase-silenced cells. Figures Figure S2 and Table S1 . 
Distance ( (C) Profiles of the histone modifications indicated above each panel, and those of RNAPII across the TSS for DYRK1A-associated genes (in red) and for random Ensemble genes (in black) (see also Figure S3A ). (D) DYRK1A protein levels were downregulated in T98G cells by lentiviral delivery of two different shRNAs, assessing the depletion in immunoblots (*crossreacting band). The expression of selected DYRK1A target genes was determined by RT-qPCR (n = 2-3 biological replicates) (see Figure S3B for data on HeLa cells).
(legend continued on next page)
The biological activity of DYRK1A is highly sensitive to gene dosage variation (Courcet et al., 2012; Laguna et al., 2008) , and thus, changes in DYRK1A levels might have an impact on the expression of its target genes. Therefore, we analyzed the expression of DYRK1A target genes in ''physiological'' conditions in which DYRK1A is altered using expression data from publicly available microarray experiments for those target genes common to the HeLa and T98G ChIP-seq datasets. DYRK1A is overexpressed by 1.5-fold in the fetal and adult brain of DS individuals (Guimera et al., 1999) . The GEO dataset GSE5390 profiles human adult postmortem brain tissue from DS and non-trisomic control subjects (Lockstone et al., 2007) , and the microarray data reflected the increased DYRK1A expression in the DS samples ( Figure 3E ). We also searched GEO for experiments with a reduced DYRK1A expression and found that sperm cells from males with severe teratozoospermia (GSE6872; Platts et al., 2007) presented a strong reduction in DYRK1A mRNA levels (log2$À5) when compared to samples from normospermic individuals ( Figure 3E ). The analysis of the two GEO datasets showed that the expression of DYRK1A target genes correlated with the levels of DYRK1A expression, whereby target genes were upregulated when DYRK1A was overexpressed, and they were strongly downregulated when DYRK1A expression was severely dampened ( Figure 3E ). We conclude that the ChIPseq analysis has identified transcriptional targets of DYRK1A and, furthermore, that DYRK1A binding is positively associated with regulating their expression.
Enrichment of the TCTCGCGAGA Palindrome in Genomic DYRK1A Target Sequences DYRK1A could regulate transcription by phosphorylating transcription factors bound to the promoter region of its target genes, and indeed, DYRK1A phosphorylates a few transcription factors like Gli1, nuclear factor of activated T cells (NFAT) proteins, or Notch (Arron et al., 2006; Fernandez-Martinez et al., 2009; Gwack et al., 2006; Mao et al., 2002) . To determine whether the chromatin targeting of DYRK1A occurs by a mechanism involving transcription factors, we assessed whether DYRK1A-occupied genomic sequences were enriched for certain DNA motifs. De novo MEME analysis on DYRK1A ChIP-seq regions revealed significant enrichment of only one motif, corresponding to the palindromic sequence TCTCGC GAGA (p value < 2.0 3 10 À431 ; Figure 4A ). This motif was not distributed uniformly within the genomic categories identified in the DYRK1A ChIP-seq since more than 80% of the DYRK1A-associated promoters contained the consensus sequence, but only 6% of the intergenic regions had it (Figure 4B) , suggesting a regulatory role for this palindrome. Most of the DYRK1A peaks contain more than one consensus motif ( Figure 4C ), and this palindromic motif was highly conserved in placental mammals ( Figure S4A ), suggesting a high degree of functional conservation. In addition, we observed a precise positioning of the motif around the center of the DYRK1A peaks ( Figure 4D ), an indication of a role in DYRK1A recruitment.
To assess the functional role of this putative DYRK1A binding site, we tested the ability of the TCTCGCGAGA motif to interact with proteins in HeLa cell nuclear extracts using electrophoretic mobility shift assays (EMSAs). A double-strand oligonucleotide containing the palindromic consensus sequence formed two different DNA-protein complexes ( Figure 4E ) that were competed out by excess unlabeled wild-type probe, yet not by a non-consensus probe ( Figure S4B ). Pre-incubation of the nuclear extracts with two different antibodies that immunoprecipitate DYRK1A ( Figure S4C ) either prevented the formation of the DNA-protein complexes (mouse antibody) or enhanced the intensity of the shifted band and induced the appearance of a retarded band (as a result of antibody-mediated supershift and/or stabilization of complex II) ( Figure 4F ). Concurring with the behavior in the EMSA experiments, the mouse anti-DYRK1A antibody did not work in ChIP experiments ( Figures S4D-S4F ). Thus, we conclude that DYRK1A participates in protein complexes formed at the TCTCGCGAGA sequence.
We examined the relevance of the palindromic sequence in DYRK1A-mediated transcriptional activity in vivo using a cellbased luciferase assay in which the putative regulatory region of the RPS11 gene (À450 to +25) that harbors two TCTCGCG AGA motifs was cloned upstream of the luciferase gene (Figure 4G) . While this genomic fragment drove luciferase expression, removal of the consensus sequences reduced the transcriptional activity of the reporter (Figure 4G ), indicating a functional role for the palindrome in transcriptional activation. In fact, the consensus sequence alone was able to drive expression in luciferase reporter assays ( Figure S4G ). To provide experimental evidence of a link between the TCTCGCGAGA motif and DYRK1A regulation, we tested the activation of the RPS11 reporter in cells depleted of DYRK1A. Luciferase levels were reduced in parallel with the loss of DYRK1A, whereas there was little or no change when the mutant reporter without the consensus sequence was used ( Figures 4H and S4G) . When the impact of DYRK1A kinase activity was assessed in overexpression experiments, luciferase activity was enhanced when the WT version of DYRK1A was overexpressed, whereas there was no effect or even a reduction when the reporter was cotransfected with a kinase-inactive construct ( Figure 4I ). Consistent with the DYRK1A depletion assays, none of these effects were observed when the mutant reporter was used ( Figure 4I ). Taken together, these results indicate that the TCTCGCGAGA consensus sequence is necessary to drive DYRK1A-dependent transcriptional activation.
DYRK1A Recruitment to Its Target Genes Is Independent of Cell Growth Conditions
To gain further insight into the biological role of DYRK1A when recruited to chromatin, we calculated the enrichment of gene (E) Correlation analysis of the expression of DYRK1A and its targets. For DYRK1A overexpression, data from DS individuals were used (GSE5390), while for DYRK1A downregulation the GEO dataset GSE6872 was used. The expression data are represented as the fold change (log2) (expression scale) in each of the DS brain samples with respect to the average level of DYRK1A expression in the non-trisomic samples (left panel), or in each of the teratozoospermic samples with respect to the average level of DYRK1A expression of the normospermic samples in the dataset (right panel). The correlation analysis is represented as Z score values for the preferential expression of DYRK1A target genes defined in a colored heatmap (see also Figure S3C for expression analysis in tissues).
ontology (GO) terms for the genes that bind DYRK1A. Among the DYRK1A-bound genes, there was a significant enrichment in GO terms associated with translation (e.g., DENR, EIF4A3, and RPS6), RNA splicing (e.g., SF1, CDC5L, and SRSF10) and cell cycle (e.g., NCAGP, CDC26, and SMC4) ( Figure 5A ). Indeed, DYRK1A has been associated with the phosphorylation of molecules regulating cell-cycle progression (Chen et al., 2013; Litovchick et al., 2011; Soppa et al., 2014) , and hence, we assessed the transcriptional activation of DYRK1A target genes in proliferating and serum-starved T98G cells. The expression of several of the target genes tested was reduced in resting conditions (Figure 5B) , a reduction comparable to that observed when DYRK1A was knocked down ( Figure 5B ). However, DYRK1A depletion did not further reduce the expression of the target genes under serum starvation conditions ( Figure 5B ). Since DYRK1A knockdown did not lead to a defect in cell proliferation ( Figures S5B and S5C) , we rule out that the reduction in transcript levels is the result of changes in the proliferative status of the cells. All together, these results indicate that DYRK1A would be required for full expression of its target genes under normal growth conditions. These data suggest that DYRK1A may not be recruited to the target chromatin loci in resting conditions, which we tested by comparing DYRK1A ChIP-seq data from proliferating and serum-starved T98G cells. A strong overlap of peaks was observed between the two datasets, since 75% of the peaks found in serum-starved conditions were also found in proliferating conditions ( Figure 5C ). Moreover, the association with promoters was strongly enriched within the overlapping peaks (85%), whereas only 9% of the serum-starved-specific peaks corresponded to promoter regions ( Figure S5A ). ChIP-qPCR validated the kinase promoter occupancy of several target genes to a similar extent in the two different growth conditions (Figure 5D ). Although no changes in DYRK1A protein levels were observed when the two growth conditions were compared (Figures S5D and S5E) , a reduction in the activity of DYRK1A was detected when the kinase purified from proliferating conditions was compared to that from resting cells ( Figure 5E ). In addition, treatment of the cells with the DYRK inhibitor harmine did not affect the recruitment of DYRK1A to its target regions ( Figure 5F ), suggesting that kinase activity is not required for DYRK1A association to chromatin. Hence, while DYRK1A recruitment to its target promoters may be constitutive, its kinase activity may differ in proliferating and resting conditions, resulting in differences in DYRK1A-transcriptional activity.
DYRK1A Phosphorylates the CTD of RNAPII
Given the kinase dependence observed in the reporter assays, we hypothesized that DYRK1A phosphorylation of at least one protein at the promoter would underlie its transcriptional activity. We first considered the possibility that DYRK1A fulfilled an epigenetic role by phosphorylating histones. In fact, DYRK1A phosphorylates in vitro H3 only at Thr45 (Himpel et al., 2000) , and it was recently reported that DYRK1A acts as a transcriptional regulator by phosphorylating H3T45, resulting in increased H3Ac and antagonizing heterochromatin protein 1 binding (Jang et al., 2014) . Depletion of DYRK1A did not induce changes in either H3 phosphorylation or H3/H4 acetylation at the cellular level (Figure S7A) . Moreover, no ChIP changes were observed with an anti-H3T45p commercial antibody on the target genes upon DYRK1A depletion ( Figure 6A ; though the antibody produced very low ChIP signals). Finally, no reduction in the levels of H3Ac on the target gene promoters was observed upon DYRK1A knockdown ( Figure 6B ), indicating that a repressive chromatin state had not been induced. The fact that the DYRK1A targets identified in Jang et al. (2014) were not present in our ChIP-seq dataset, and that they do not harbor the TCTCGCGAGA motif, opens the possibility of DYRK1A regulating transcription through different mechanisms depending on its recruitment mode.
The overlap of DYRK1A-and RNAPII-bound genomic regions in target promoters ( Figure 3A) suggested that the RNAPII CTD might be a DYRK1A substrate. The mammalian RNAPII CTD consists of 52 hepta-residue repeats (YSPTSPS), and its phosphorylation governs the ''paused'' or ''elongating'' phases of the transcription cycle (reviewed in Hsin and Manley, 2012) . Coimmunoprecipitation experiments indicated that DYRK1A interacts with RNAPII independently of its kinase activity ( Figure 6C) . Moreover, the interaction was strongly reduced when an antibody recognizing hypophosphorylated RNAPII (8WG16) was used ( Figure 6C ). This result could be explained either by the inability of DYRK1A to interact with the hypophosphorylated RNAPII pool or because DYRK1A is competing with the antibody for the interaction with the CTD. To test this hypothesis, we used pull-down experiments with GST-CTD expressed in bacteria as bait and found that DYRK1A did interact with the RNAPII CTD in a kinase-independent manner ( Figures 6D and  S6B ). To determine whether DYRK1A is able to directly phosphorylate the RNAPII CTD, we performed IVK assays with purified DYRK1A and the GST-CTD fusion protein as substrate and analyzed the reactions with antibodies to all the putative CTD phosphoresidues. Addition of increasing amounts of DYRK1A WT, but not of a kinase-inactive mutant, led to dose-dependent phosphorylation of GST-CTD at Ser2 and Ser5, and to a lesser extent at Ser7, while no signals over controls were detected for Tyr1p ( Figure 6E ; we were unable to obtain trustable results for Thr4p). The DYRK1A preference for Ser2p and Ser5p is in agreement with DYRK1A favoring Pro residues at the +1 position of its phosphorylation motif (Himpel et al., 2000) . Notably, the DYRK1A-phosphorylated CTD was also detected with the H5 antibody ( Figure S6E ), which has greater affinity for CTD phosphorylated at both Ser2 and Ser5 rather than Ser2 alone (Chapman et al., 2007) , suggesting that DYRK1A could phosphorylate both residues within the same repeat, at least in vitro. Moreover, the large band shift observed upon phosphorylation indicates that DYRK1A can phosphorylate several of the hepta-repeats in the same molecule, as it has been described for the CTD kinase CDK9 (Czudnochowski et al., 2012) . We conclude that DYRK1A phosphorylates the RNAPII CTD at Ser2 and Ser5.
The class I DYRK1B also interacted with RNAPII, very likely through the CTD (Figures S6A and S6B) , and when assayed in IVK assays, it phosphorylated the same CTD residues as DYRK1A ( Figure S6D) . It is therefore possible that the transcriptional activity shown by both kinases in the one-hybrid assay ( Figure 1G ) relies on the same molecular mechanism. As in the case of DYRK1A, a small pool of DYRK1B is present in the nucleus ( Figure S6C ). Hence, we evaluated the possibility of DYRK1B to be recruited to DYRK1A target genes, but no ChIP signals were detected (Figures S6G-S6J ). Although we cannot formally exclude that the anti-DYRK1B antibody did not work in ChIP, the results raise the intriguing possibility of type I DYRKs regulating transcription by a mechanism similar to that of CTD kinases but on different subset of genes, which could be selected based on specific DNA sequences at promoter regions.
DYRK1A Depletion Reduces Hyperphosphorylated RNAPII at Target Promoters
When we examined whether the absence of DYRK1A affects global levels of RNAPII CTD phosphorylation, we found that 
H3-T45p/H3
(relative enrichment to shControl) Figure 6 . DYRK1A Interacts with and Phosphorylates the RNAPII CTD (A) DYRK1A depletion does not affect the phosphorylation of H3 at Thr45 on target promoters. The presence of H3 and H3T45p at DYRK1A target promoters was assessed by ChIP, and the data are represented as the ratio of H3T45p/H3. (B) DYRK1A depletion does not affect the acetylation status of H3 at its target promoters. The presence of H3 and H3-Ac at DYRK1A target promoters was assessed by ChIP, and the data are represented as the ratio of H3-Ac/H3. In (A) and (B), values in T98G cells infected with a shControl lentivirus were set at 1 for each gene, and values from the shDYRK1A-lentivirus-infected cells were expressed relative to them (mean ± SD of two independent experiments). (C) DYRK1A interacts with the RNAPII CTD. Extracts from HEK293T cells overexpressing DYRK1A (WT) or a kinase-inactive mutant (KR) were immunoprecipitated with an antibody directed to the N-terminal region of RNAPII (N20) or with 8WG16, which recognizes mostly RNAPIIa. See also Figures S6A and S6B for results on the DYRK1A paralog, DYRK1B. (D) Pull-down experiments with unfused GST or GST-CTD and with the proteins indicated, in which the bound proteins were detected by autoradiography. Cyclin T1 is used as a positive control for the interaction with the unphosphorylated CTD, while cyclin L2 only interacts with hyperphosphorylated CTD. (E) DYRK1A phosphorylates the RNAPII CTD. IVK assay using increasing amounts of bacterially expressed GST-DYRK1A (WT) or a kinase-death mutant (KR) and the GST-CTD fusion protein as the substrate. Equivalent aliquots of the reaction were analyzed in immunoblots probed with the antibodies indicated. The asterisk indicates the non-phosphorylated GST-CTD. The sequence of the CTD hepta-repeat is included. The shift in DYRK1A
WT electrophoretic mobility is due to autophosphorylation. See also Figure S6D for results with DYRK1B.
(F) The presence of the RNAPII catalytic subunit and the phosphorylation of the indicated residues within the CTD were analyzed by immunoblot in total cell extracts from cells expressing a shRNA control or two shRNAs to DYRK1A. The position of the RNAPII IIa and IIo is indicated.
DYRK1A knockdown did not change the levels of either CTD phosphoresidue significantly ( Figures 6F and S6F ), pointing at DYRK1A effects on CTD phosphorylation only occurring at the chromatin level.
The presence of RNAPII in the DYRK1A-target regions was confirmed by ChIP-qPCR using an antibody detecting both RNAPIIa and IIo (N20) (Figures 7A and S7B) . Notably, the recruitment of RNAPII was reduced in cells depleted of DYRK1A, whereas RNAPII occupancy at the promoter of genes not bound by DYRK1A was not affected (Figure 7A ), indicating that the reduction in DYRK1A levels could impact negatively on the association of the preinitiation complex (PIC) with promoters. This effect is likely the result of a DYRK1A scaffolding activity since both DYRK1A WT and a kinase-inactive mutant rescued the levels of RNAPII at the promoter regions ( Figures 7B-7D ). Such a scaffolding activity is indeed supported by the transcriptional activity shown by a DYRK1A inactive mutant in the onehybrid reporter assays ( Figures S1E-S1G ). Therefore, DYRK1A might potentiate PIC formation and/or PIC stability at promoters and hence transcriptional initiation, an effect described for CDK7/Kin28, the TFIIH kinase subunit (Larochelle et al., 2012; Wong et al., 2014) .
To analyze the effect of DYRK1A on CTD phosphorylation locally, we performed ChIP assays with Ser2 and Ser5 antibodies along three target genes. In DYRK1A-depleted cells, there was a significant reduction of both . Consistent with a requirement for DYRK1A phosphorylation, Ser2p and Ser5p levels were recovered upon re-expression of DYRK1A WT, but not of a kinaseinactive mutant (Figures 7E-7G) . We conclude that the combination of the loss of RNAPII association to the target promoters together with the reduced CTD phosphorylation of the elongating RNAPII would be responsible for the reduced expression of the target genes upon DYRK1A depletion.
DISCUSSION
We demonstrate here that DYRK1A is active as a kinase in the nucleus and, furthermore, that it participates in distinct nuclear macromolecular complexes, including those containing the RNAPII holoenzyme. Through genome-wide profiling of DYRK1A-chromatin interactions, we show that DYRK1A is preferentially recruited to proximal promoter regions, in close proximity to TSSs, and characterized by the presence of the palindromic TCTCGCGAGA sequence. This motif is very similar to the TMTCGCGANR motif previously identified as one of the top ten most strongly enriched and well-conserved motifs in human promoters (Pique-Regi et al., 2011; Xie et al., 2005) , also proposed to be a potential cis-regulatory element in 5% of human genes (Roepcke et al., 2006; Wyrwicz et al., 2007) and to be related to Drosophila DRE (DNA replication-related element) in ribosomal protein genes (Yamashita et al., 2007) . Despite our inability to detect direct binding of DYRK1A to this regulatory sequence, we consider that the TCTCGCGAGA motif is most likely to be the genomic sequence responsible for the recruitment of DYRK1A to target promoters, based on the central position of the motif within the DYRK1A-ChIP sequences and on the EMSA results.
No classic DNA binding domains are detected in the primary structure of DYRK1A, yet we cannot rule out the existence of unconventional ones, such as that identified in ERK2 (Hu et al., 2009) . Alternatively, a DNA binding protein might mediate the association of DYRK1A to the consensus DNA motif at specific genomic locations. In this regard, and within the framework of the ENCODE project, the transcriptional repressor KAISO/ ZBTB33 and two other transcriptional modulators, CHD2 and BRCA1, were identified as putative TCTCGCGAGA interacting factors (Wang et al., 2012) . KAISO was also found bound to TCTCGCGAGA-containing pre-adipocyte-specific promoters (Raghav et al., 2012) . DYRK1A can interact with KAISO and its p120-catenin partner when overexpressed, allowing p120-catenin to relieve KAISO-mediated repression of Wnt target genes (that do not have the TCTCGCGAGA motif) (Hong et al., 2012) . While we did detect the interaction of DYRK1A with p120-catenin in nuclear extracts, KAISO was not detected in the DYRK1A immunoprecipitates ( Figure S4H ), indicating that KAISO and DYRK1A do not interact in nuclear extracts under the conditions tested.
Both the reporter assays and the DYRK1A knockdown experiments suggest that DYRK1A positively regulates the expression of its target genes, consistent with in silico evidence that DYRK1A expression correlates with that of its target genes. Thus, DYRK1A target genes are expressed more strongly in those tissues/cells in which more DYRK1A is expressed (hematopoietic lineage, including B cells, CD4+, and CD8+ T lymphocytes) and that they are weakly expressed in those tissues with little DYRK1A (lung or skeletal muscle; Figures S3C and S3D) . Moreover, we observed a strong correlation in pathological situations in which different DYRK1A levels are found. These findings suggest that the downstream physiological effects of the gain or loss of DYRK1A could partly operate through the direct alteration of specific gene transcription profiles, thereby widening the spectrum of DYRK1A cellular activities.
Our results are in agreement with DYRK1A acting at the level of RNAPII recruitment to regulate its target genes, independently of its kinase activity, as a consequence of its ability to directly interact with the CTD and/or through the requirement to maintain chromatin-bound levels of PIC components. This activity also raises the intriguing possibility of the TCTCGCGAGA motif acting as an element of core promoters, due to its close proximity to the TSS in many of the genes harboring the motif. Moreover, and although we are aware that DYRK1A might have other indirect effects that alter CTD phosphorylation (e.g., local activation of other CTD kinases or inhibition of CTD phosphatases) or that may even be independent of the CTD, our data are consistent with DYRK1A being a gene-specific CTD kinase, as in the case of CDK12 or ERK2 (Blazek et al., 2011; Tee et al., 2014) . The dynamic phosphorylation of residues in the CTD hepta-repeats has a fundamental role on the transcription cycle (reviewed in Hsin and Manley, 2012) . In particular, phosphorylation of Ser2 is critical to overcome proximal promoter pausing and for the subsequent processivity of the elongating polymerase. Our results would therefore be compatible with DYRK1A working as an ''elongation factor.'' Whether DYRK1A phosphorylation is linked to promoter escape or to RNAPII processivity remains to be investigated in future studies. Moreover, CTD phosphorylation is linked to co-transcriptional RNA processing by helping to recruit splicing and polyadenylation factors (Hsin and Manley, 2012) . In this regard, it is worth mentioning that DYRK1A accumulates in nuclear speckles and interacts with and phosphorylates splicing factors (Qian et al., 2011) , and it would be interesting to explore whether DYRK1A modulates splicing co-transcriptionally. The dataset of DYRK1A genomic targets revealed a strong enrichment for a group of genes related to ribosomal biogenesis and translational regulation. Interestingly, genetic manipulation in flies and mice has shown that defects in signaling pathways that control these processes provoke defects in body size (Lloyd, 2013) . In this regard, minibrain (the DYRK1A ortholog) mutant flies and Dyrk1a heterozygous mice are smaller than their wildtypes (Fotaki et al., 2002; Tejedor et al., 1995) . The regulation of size in a multicellular organism is a complex issue involving the control of cell size and cell number (reviewed in Lloyd, 2013) . DYRK1A has already been linked to cell-cycle regulation, as it phosphorylates proteins such as cyclin D1, p27, or components of the DREAM complex (Chen et al., 2013; Litovchick et al., 2011; Soppa et al., 2014) . Our data widen the context of DYRK1A activity by suggesting that this kinase could act as a modulator of both cell growth and cell division.
EXPERIMENTAL PROCEDURES
The plasmids used here, as well as the procedures for cell transfection, lentiviral infection, and other cell analyses, can be found in the Supplemental Experimental Procedures, along with a detailed explanation of the immunoblot analysis, immunoprecipitation, and IVK assays and the sequences of the primers for ChIP-qPCR and RT-PCR.
Luciferase Reporter Assays
Cells were co-transfected with the luciferase reporter vectors and with the effector plasmids, using a Renilla expression vector (pRL Null; Promega) to normalize for transfection efficiencies. Each transfection point was performed in triplicate, and each experiment was repeated at least three times. Luciferase and Renilla activities were determined in cell lysates by the dual-luciferase reporter assay system (Promega), and bioluminescence was analyzed on an AutoLumat LB 953 luminometer (Berthold Technologies). Values are given as the mean ± SD.
ChIP-Seq and ChIP-qPCR ChIP assays were performed on approximately 10 8 HeLa or T98G cells per experiment. Briefly, cells were crosslinked in 1% formaldehyde for 15 min, and the cell extracts were processed as described in the Supplemental Experimental Procedures. The total protein (600 mg) was diluted in 1 ml of IP buffer and immunoprecipitated overnight at 4 C with an antibody against DYRK1A or control immunoglobulin G (IgG). The immune complexes were recovered and purified, and the eluted material was phenol/chloroform extracted and ethanol precipitated.
For the ChIP-seq analysis, DYRK1A-bound chromatin from 10 8 cells was prepared for library construction. Details on read mapping, peak calling, and data analysis can be found in the Supplemental Experimental Procedures. For ChIP-qPCR, a fraction of the chromatin was used in qPCR experiments performed with SYBR Green. The results are presented as the percentage of the input material.
Reverse Transcription and RT-qPCR Superscript II Reverse Transcriptase (RT) was used to synthesize cDNAs from the total RNA (500 ng), which were analyzed by RT-qPCR performed in triplicate with SYBR Green in 384-well plates using the Roche LC-480 equipment (Roche Applied Science). The mRNA expression of target genes was normalized to that of GAPDH/EF1a, and the data are represented as the mean ± SD of biological replicates.
ACCESSION NUMBERS
The GEO accession number for the ChIP-seq data reported in this paper is GSE63712. 
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